Drug
Egf816
Egf816: highest development phase Phase 1, developed by Novartis. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Novartis
Trials
| Drug | Phase | Indication |
|---|---|---|
| EGF816 NCT03333343 | Phase 1 | EGFR-mutant Non-small Cell Lung Cancer |
Latest
No recent events.
Follow Egf816 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.